0001209191-20-018227.txt : 20200311 0001209191-20-018227.hdr.sgml : 20200311 20200311175714 ACCESSION NUMBER: 0001209191-20-018227 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200309 FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hirsch Stanley CENTRAL INDEX KEY: 0001727864 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 20706505 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Menlo Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CARDINAL WAY, 2ND FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-486-1416 MAIL ADDRESS: STREET 1: 200 CARDINAL WAY, 2ND FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-09 0 0001566044 Menlo Therapeutics Inc. MNLO 0001727864 Hirsch Stanley 200 CARDINAL WAY, 2ND FLOOR REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2020-03-09 4 A 0 31303 A 31303 D Common Stock 2020-03-09 4 A 0 108113 A 108113 I See footnote Common Stock 2020-03-09 4 A 0 34960 A 66263 D Stock Options 9.93 2020-03-09 4 A 0 15994 A 2020-03-09 2024-12-29 Common Stock 15994 15994 D Stock Options 7.92 2020-03-09 4 A 0 48667 A 2027-07-13 Common Stock 48667 48667 D Stock Options 8.48 2020-03-09 4 A 0 29481 A 2020-03-09 2028-05-08 Common Stock 29481 29481 D Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. /s/ Mutya Harsch, attorney-in-fact for Stanley Hirsch 2020-03-11